For the most part Tuesday, biotech stocks finished in the green, following the broader market higher. The Nasdaq Biotechnology Index finished the day down 5.76 points at 914.15.
(ALXA - Get Report) stock continued to decline after
Monday's bloodbath, sparked by the
FDA's decision to deny approval of the company's schizophrenia treatment.
By the closing bell Tuesday, Alexca shares paired earlier losses, finishing the session down 3% to $1.34 in another day of frantic trading. Investors wiped out half the company's market value during the previous session.
Elsewhere in the world of experimental tinctures,
(GERN - Get Report) stock continued to climb in the wake of the stem-cell drug developer's historic launch of human clinical trials Monday.
The stock closed at $6.37, adding another 12% Tuesday. Volume in Geron shares Tuesday was heavy again, surpassing 9 million. Average daily turnover is about 1 million.
-- Written by Scott Eden in New York
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to: